[{"orgOrder":0,"company":"Glyscend Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glyscend Therapeutics Releases New Phase 1 Biomarker Results and Initiates Phase 2 Clinical Trial Under an IND for GLY-200 as a Potential First-in-Class Type 2 Diabetes Treatment","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II"},{"orgOrder":0,"company":"Glyscend Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glyscend Therapeutics Announces Positive Topline Phase 2a Clinical Results and Progress with GLY-200, a First-in-Class Treatment for Type 2 Diabetes and Obesity","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by Glyscend Therapeutics
GLY-200 is an oral, proprietary mucin-complexing polymer and first and only clinical-stage, potentially disease-modifying, pharmacologic polymer therapy in clinical development for the treatment of type 2 diabetes and obesity.
Glyscend reported key results from the study indicating that 5-days dosing with GLY-200 resulted in statistically significant effects on glucose, insulin, and bile acids, and was associated with changes in gut hormones such as GLP-1 and glicentin compared to placebo.